Predictive Technology Group (Predictive Technology Group) Total Liabilities : $35.09 Mil (As of Mar. 2021)

View and export this data going back to 2007. Start your Free Trial

What is Predictive Technology Group Total Liabilities?

Predictive Technology Group's Total Liabilities for the quarter that ended in Mar. 2021 was $35.09 Mil.

Predictive Technology Group's quarterly Total Liabilities increased from Sep. 2020 ($32.02 Mil) to Dec. 2020 ($32.57 Mil) and increased from Dec. 2020 ($32.57 Mil) to Mar. 2021 ($35.09 Mil).

Predictive Technology Group's annual Total Liabilities increased from Jun. 2018 ($22.65 Mil) to Jun. 2019 ($31.04 Mil) but then declined from Jun. 2019 ($31.04 Mil) to Jun. 2020 ($28.92 Mil).

Predictive Technology Group Total Liabilities Historical Data

The historical data trend for Predictive Technology Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Technology Group Total Liabilities Chart

Predictive Technology Group Annual Data

Trend

Aug06

Aug07

Jun16

Jun17

Jun18

Jun19

Jun20

Total Liabilities

Get a 7-Day Free Trial

0.10

1.13

22.65

31.04

28.92

Predictive Technology Group Quarterly Data
	Nov07	Feb08	May08	Jun16	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Total Liabilities	Get a 7-Day Free Trial															23.15	28.92	32.02	32.57	35.09

Predictive Technology Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Predictive Technology Group's Total Liabilities for the fiscal year that ended in Jun. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	20.836	+	(5.571	+	2.211
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.301	+	0)
	=	28.92

Total Liabilities	=	Total Assets (A: Jun. 2020 )	-	Total Equity (A: Jun. 2020 )
	=	83.842	-	54.923
	=	28.92

Predictive Technology Group's Total Liabilities for the quarter that ended in Mar. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	30.629	+	(3.325	+	0.834
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.301	+	0)
	=	35.09

Total Liabilities	=	Total Assets (Q: Mar. 2021 )	-	Total Equity (Q: Mar. 2021 )
	=	66.959	-	31.869
	=	35.09

Predictive Technology Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Predictive Technology Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Technology Group (Predictive Technology Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Predictive Technology Group Inc (OTCPK:PRED) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109

Website

https://www.predtechgroup.com

Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.